Zhongyuan Wen

Dr. Zhongyuan Wen


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2012 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
YCYuli Cai
Yuli Cai
XHXiaorong Hu
Xiaorong Hu
BYBo Yi
Bo Yi
TZTing Zhang
Ting Zhang
ZWZhongyuan Wen
Zhongyuan Wen

14 January 2014 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
TZTing Zhang
Ting Zhang
XHXiaorong Hu
Xiaorong Hu
YCYuli Cai
Yuli Cai
BYBo Yi
Bo Yi
ZWZhongyuan Wen
Zhongyuan Wen

31 July 2014 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
BYBo Yi
Bo Yi
XHXiaorong Hu
Xiaorong Hu
ZWZhongyuan Wen
Zhongyuan Wen
TZTing Zhang
Ting Zhang
YCYuli Cai
Yuli Cai
Activation of the receptor for advanced glycation end products (RAGE) axis may have an important role in apoptosis. Glucagon-like peptide-1 (GLP-1) is a gut hormone that has been proposed as a therapeutic target for the treatment of diabetes, and GLP-1 receptor agonists have been reported to protect against myocardial injury associated with diabetes. The aim of the present study was to investigate the cardioprotective mechanism of exendin-4 (EX-4), a GLP-1 receptor agonist, against myocardial cell apoptosis induced by hyperglycemia. Neonatal rat ventricular myocytes were prepared by enzymatic dissociation and then cultured with high levels of glucose (HG) in the presence or absence of EX-4. Cell apoptosis was detected using an annexin V-fluorescein isothiocyanate/propidium iodide kit, and cell viability was measured using an MTT assay. RAGE expression levels and the activity of caspase-3 were assessed by western blot analysis. The results demonstrated that the incubation of myocytes with HG led to a time-dependent activation of RAGE, and the protein expression of RAGE was increased at 6 h and peaked at 24 h (P<0.05). Hyperglycemia was also found to significantly decrease cell viability and increase apoptosis (P<0.05). In addition, EX-4 significantly inhibited hyperglycemia-induced RAGE expression and the apoptosis of myocytes, and improved cell viability in a dose-dependent manner (P<0.05). When the concentration of EX-4 was 10 nM, the myocardial cell viability was significantly improved, and the levels of RAGE expression and apoptosis were significantly decreased compared with those in the HG group in the absence of EX-4 (P<0.05). Therefore, the results from the present study suggest that the cardioprotective effect induced by EX-4, a GLP-1 receptor agonist, against diabetic cardiomyopathy may be associated with the inhibition of RAGE expression.

22 August 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
BYBo Yi
Bo Yi
KSKe Su
Ke Su
YCYu-Li Cai
Yu-Li Cai
XCXiao-Ling Chen
Xiao-Ling Chen
YBYan Bao
Yan Bao
ZWZhongyuan Wen
Zhongyuan Wen

20 December 2017 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
YCYuli Cai
Yuli Cai
TZTianshu Zeng
Tianshu Zeng
ZWZhongyuan Wen
Zhongyuan Wen
LCLu-Lu Chen
Lu-Lu Chen
Alogliptin is a highly selective, potent, and orally available dipeptidyl peptidase-4 (DPP-4) inhibitor. This study compared the glucose-lowering efficacy and safety of alogliptin between Asian and non-Asian patients with type 2 diabetes.

1 April 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
BYBo Yi
Bo Yi
GFGaoke Fen
Gaoke Fen
DCDedong Cao
Dedong Cao
YCYuli Cai
Yuli Cai
LQLi Qian
Li Qian
XSXuan Sun
Xuan Sun
To investigate the epidemiological dynamics, transmission patterns, and the clinical outcomes of Coronavirus disease 2019 (COVID-19) in familial cluster patients in Wuhan, China. Between January 22, 2020, and February 4, 2020, we enrolled 214 families for this retrospective study. The COVID-19 cases were diagnosed using real-time reverse-transcriptase polymerase chain reaction (RT-PCR). The number of COVID-19 subjects in a family, their relationship with index patients, the key time-to-event, exposure history, and the clinical outcomes were obtained through telephone calls. Overall, 96 families (44.9%) met the criteria of a familial cluster, which is at least one confirmed case in addition to the index patient in the same household. The secondary attack rate was 42.9%, and nearly 95% of index patients transmitted the infection to ≤2 other family members. High transmission pattern was noted between couples (51.0%) and among multi-generations (27.1%). The median serial interval distribution in familial clusters was 5 days (95% CI, 4 to 6). The case fatality rate was 8.7% in index patients and 1.7% in non-familial clusters patients (p = 0.023). There is a related higher attack rate and worse clinical outcomes in COVID-19 family clusters.